Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...

Income investors have liked Pfizer (NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these days has made its stock even more attractive. But when a dividend yield ...

Many income investors probably have mixed emotions about stocks with ultra-high dividend yields. On one hand, they love the tremendous income these stocks provide. On the other hand, they might worry ...

Pfizer can cover its dividends with free cash flow, but doesn't have a huge cushion. The company faces some risks from pipeline setbacks, patent expirations, and U.S. government policies. Its dividend ...

Pfizer's dividend payout ratio is high, but the company is generated enough free cash flow to cover its dividend. Management remains committed to the dividend program despite Pfizer facing a patent ...